JP2016056206A5 - - Google Patents

Download PDF

Info

Publication number
JP2016056206A5
JP2016056206A5 JP2016005132A JP2016005132A JP2016056206A5 JP 2016056206 A5 JP2016056206 A5 JP 2016056206A5 JP 2016005132 A JP2016005132 A JP 2016005132A JP 2016005132 A JP2016005132 A JP 2016005132A JP 2016056206 A5 JP2016056206 A5 JP 2016056206A5
Authority
JP
Japan
Prior art keywords
glucosidase
glycogenosis
type
acid
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016005132A
Other languages
English (en)
Japanese (ja)
Other versions
JP6163216B2 (ja
JP2016056206A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016056206A publication Critical patent/JP2016056206A/ja
Publication of JP2016056206A5 publication Critical patent/JP2016056206A5/ja
Application granted granted Critical
Publication of JP6163216B2 publication Critical patent/JP6163216B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2016005132A 2000-07-18 2016-01-14 Ii型糖原病の治療 Expired - Lifetime JP6163216B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
US60/219,237 2000-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014141336A Division JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017099515A Division JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療

Publications (3)

Publication Number Publication Date
JP2016056206A JP2016056206A (ja) 2016-04-21
JP2016056206A5 true JP2016056206A5 (https=) 2016-12-15
JP6163216B2 JP6163216B2 (ja) 2017-07-12

Family

ID=22818451

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2002511773A Expired - Lifetime JP5113312B2 (ja) 2000-07-18 2001-07-10 Ii型糖原病の治療
JP2007312804A Pending JP2008081507A (ja) 2000-07-18 2007-12-03 Ii型糖原病の治療
JP2011173569A Pending JP2012006953A (ja) 2000-07-18 2011-08-09 Ii型糖原病の治療
JP2013162201A Expired - Lifetime JP5792774B2 (ja) 2000-07-18 2013-08-05 Ii型糖原病の治療
JP2014141336A Pending JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療
JP2016005132A Expired - Lifetime JP6163216B2 (ja) 2000-07-18 2016-01-14 Ii型糖原病の治療
JP2017099515A Pending JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療
JP2017201250A Pending JP2018002749A (ja) 2000-07-18 2017-10-17 Ii型糖原病の治療
JP2018171154A Pending JP2018199721A (ja) 2000-07-18 2018-09-13 Ii型糖原病の治療
JP2019202851A Pending JP2020019822A (ja) 2000-07-18 2019-11-08 Ii型糖原病の治療

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2002511773A Expired - Lifetime JP5113312B2 (ja) 2000-07-18 2001-07-10 Ii型糖原病の治療
JP2007312804A Pending JP2008081507A (ja) 2000-07-18 2007-12-03 Ii型糖原病の治療
JP2011173569A Pending JP2012006953A (ja) 2000-07-18 2011-08-09 Ii型糖原病の治療
JP2013162201A Expired - Lifetime JP5792774B2 (ja) 2000-07-18 2013-08-05 Ii型糖原病の治療
JP2014141336A Pending JP2014185187A (ja) 2000-07-18 2014-07-09 Ii型糖原病の治療

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017099515A Pending JP2017137357A (ja) 2000-07-18 2017-05-19 Ii型糖原病の治療
JP2017201250A Pending JP2018002749A (ja) 2000-07-18 2017-10-17 Ii型糖原病の治療
JP2018171154A Pending JP2018199721A (ja) 2000-07-18 2018-09-13 Ii型糖原病の治療
JP2019202851A Pending JP2020019822A (ja) 2000-07-18 2019-11-08 Ii型糖原病の治療

Country Status (17)

Country Link
US (10) US7056712B2 (https=)
EP (4) EP2767291B1 (https=)
JP (10) JP5113312B2 (https=)
AT (1) ATE355075T1 (https=)
AU (3) AU7194101A (https=)
BR (1) BR0113006A (https=)
CA (1) CA2416492C (https=)
CY (2) CY1120977T1 (https=)
DE (1) DE60126947T2 (https=)
DK (5) DK3108895T3 (https=)
ES (5) ES2700865T3 (https=)
LT (3) LT3449934T (https=)
MX (1) MXPA03000474A (https=)
PT (5) PT3449934T (https=)
SI (3) SI3449934T1 (https=)
TW (1) TWI280882B (https=)
WO (1) WO2002005841A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767291B1 (en) * 2000-07-18 2016-09-14 Duke University Treatment of glycogen storage disease type II
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
ES2535461T3 (es) 2008-07-08 2015-05-11 Duke University Método de tratamiento de la enfermedad por almacenamiento de glucógeno
EP3679942A1 (en) * 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
EP3292871B1 (en) * 2015-05-07 2021-06-23 The University of Tokyo Nanoreactor using polyion complex polymersomes, and method for producing same
EP3344337A4 (en) * 2015-08-31 2019-03-06 Duke University METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
SG10201912761UA (en) 2016-04-15 2020-02-27 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
SMT202300187T1 (it) 2017-05-15 2023-07-20 Amicus Therapeutics Inc Alfa-glucosidasi acida umana ricombinante
KR102883778B1 (ko) 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
IT202300005733A1 (it) * 2023-03-27 2024-09-27 St Microelectronics Int Nv Circuito di comunicazione, sistema e procedimento corrispondenti

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AU4072499A (en) 1998-05-13 1999-11-29 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
ES2312222T3 (es) * 1998-12-07 2009-02-16 Genzyme Corporation Tratamiento de la enfermedad de pompe.
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
EP2767291B1 (en) * 2000-07-18 2016-09-14 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Similar Documents

Publication Publication Date Title
JP2016056206A5 (https=)
JP2013231081A5 (https=)
JP2015521607A5 (https=)
JP2011528896A5 (https=)
JP2011528895A5 (https=)
JP2012102122A5 (https=)
JP2013155188A5 (https=)
JP2016539156A5 (https=)
JP2016514132A5 (https=)
Gane et al. Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor: LB-19
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
JP2011528897A5 (https=)
RU2018103081A (ru) Способы лечения колитов
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
JP2018509388A5 (https=)
JP2018090566A5 (https=)
ZA202210024B (en) Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JP2016538840A5 (https=)
JP2013100370A5 (https=)
JP2018522881A5 (https=)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
JP2022512158A5 (https=)
MD3803G2 (ro) Metodă de tratament al hiperchineziilor la copii
JP2017530142A5 (https=)